Literature DB >> 2923288

Recovery of airway protection compared with ventilation in humans after paralysis with curare.

E G Pavlin1, R H Holle, R B Schoene.   

Abstract

d-Tubocurarine (dTc) was administered intravenously to six healthy unanesthetized volunteers to assess the sensitivity to neuromuscular blockade of those muscles involved in protecting the airway against obstruction and/or aspiration relative to the muscles of inspiration. Each subject was given an intravenous bolus of dTc followed by an infusion to allow three different levels of inspiratory muscle weakness as measured by maximum inspiratory pressure (MIP). Levels of MIP were control (-90 cm H2O), -60, -40, and -20 cm H2O. Vital capacity (VC), hand grip strength (HGS), and end-tidal CO2 (PETCO2) were obtained at each level. At each level of weakness and at intermediate values during recovery, muscles of airway protection were functionally assessed by noting the MIP at which the maneuver could be accomplished and the MIP at which they could not. The mean of these two values was calculated for each subject. The tests were: 1) ability to swallow, 2) ability to perform a valsalva maneuver, 3) prevent obstruction of the airway, and 4) ability to approximate teeth. These were compared with head lift and straight leg raising. At maximum neuromuscular blockade (MIP of -20 cm H2O), VC was 2.0 liters, HGs was 0, and PETCO2 was normal. Muscles of airway protection were still incapacitated. Swallowing returned above MIP of -43 cm H2O, approximation of teeth above -42 cm H2O, airway obstruction above -39 cm H2O, and valsalva above -33 cm H2O. Thus, although ventilation may be adequate at MIP = -25 mmHg, the muscles of airway protection are still nonfunctional.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2923288     DOI: 10.1097/00000542-198903000-00002

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  17 in total

Review 1.  Monitoring, new drugs, and reversal of neuromuscular blocking drugs.

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

2.  Comparison of integrated evoked EMG between the hypothenar and facial muscle groups following atracurium and vecuronium administration.

Authors:  M D Sharpe; C A Moote; A M Lam; P H Manninen
Journal:  Can J Anaesth       Date:  1991-04       Impact factor: 5.063

Review 3.  Muscle relaxant use during intraoperative neurophysiologic monitoring.

Authors:  Tod B Sloan
Journal:  J Clin Monit Comput       Date:  2012-09-27       Impact factor: 2.502

Review 4.  Anaesthesia and myasthenia gravis.

Authors:  A Baraka
Journal:  Can J Anaesth       Date:  1992-05       Impact factor: 5.063

Review 5.  Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

6.  Duration of succinylcholine and vecuronium blockade but not potency correlates with the ratio of endplate size to fibre size in seven muscles in the goat.

Authors:  C Ibebunjo; C B Srikant; F Donati
Journal:  Can J Anaesth       Date:  1996-05       Impact factor: 5.063

7.  Correlation between integrated evoked EMG and respiratory function following atracurium administration in unanaesthetized humans.

Authors:  M D Sharpe; A M Lam; J F Nicholas; D C Chung; R Merchant; W Alyafi; R Beauchamp
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

8.  Neuromuscular monitoring after surgery.

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1990-05       Impact factor: 5.063

Review 9.  Anaesthetic management of patients with sleep apnoea syndrome.

Authors:  N N Boushra
Journal:  Can J Anaesth       Date:  1996-06       Impact factor: 5.063

Review 10.  Neuromuscular monitoring: an update.

Authors:  Mădălina Duţu; Robert Ivaşcu; Oana Tudorache; Darius Morlova; Alina Stanca; Silvius Negoiţă; Dan Corneci
Journal:  Rom J Anaesth Intensive Care       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.